Literature DB >> 20650875

Mesenchymal stem cells in the treatment of autoimmune diseases.

Alan Tyndall, Frederic A Houssiau.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20650875     DOI： 10.1136/ard.2010.132639

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  15 in total

Review 1.  The stem cell niche should be a key issue for cell therapy in regenerative medicine.

Authors:  José Becerra; Leonor Santos-Ruiz; José A Andrades; Manuel Marí-Beffa
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

2.  Mesenchymal stem cells express serine protease inhibitor to evade the host immune response.

Authors:  Najib El Haddad; Dean Heathcote; Robert Moore; Sunmi Yang; Jamil Azzi; Bechara Mfarrej; Mark Atkinson; Mohamed H Sayegh; Jeng-Shin Lee; Philip G Ashton-Rickardt; Reza Abdi
Journal:  Blood       Date:  2010-11-12       Impact factor: 22.113

Review 3.  Stem cell-based tissue engineering approaches for musculoskeletal regeneration.

Authors:  Patrick T Brown; Andrew M Handorf; Won Bae Jeon; Wan-Ju Li
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

4.  Allogeneic cell therapy: a new paradigm in therapeutics.

Authors:  Vasileios Karantalis; Ivonne Hernandez Schulman; Wayne Balkan; Joshua M Hare
Journal:  Circ Res       Date:  2015-01-02       Impact factor: 17.367

5.  HCELL Expression on Murine MSC Licenses Pancreatotropism and Confers Durable Reversal of Autoimmune Diabetes in NOD Mice.

Authors:  Reza Abdi; Robert Moore; Shinobu Sakai; Conor B Donnelly; Marwan Mounayar; Robert Sackstein
Journal:  Stem Cells       Date:  2015-05       Impact factor: 6.277

Review 6.  In situ guided tissue regeneration in musculoskeletal diseases and aging : Implementing pathology into tailored tissue engineering strategies.

Authors:  Franz Jakob; Regina Ebert; Maximilian Rudert; Ulrich Nöth; Heike Walles; Denitsa Docheva; Matthias Schieker; Lorenz Meinel; Jürgen Groll
Journal:  Cell Tissue Res       Date:  2011-10-20       Impact factor: 5.249

Review 7.  Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.

Authors:  Raphael Gorodetsky; Wilhelm K Aicher
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

8.  Gain of CXCR7 function with mesenchymal stem cell therapy ameliorates experimental arthritis via enhancing tissue regeneration and immunomodulation.

Authors:  Sung-Tai Wei; Yen-Chih Huang; Jung-Ying Chiang; Chia-Ching Lin; Yu-Jung Lin; Woei-Cherng Shyu; Hui-Chen Chen; Chia-Hung Hsieh
Journal:  Stem Cell Res Ther       Date:  2021-05-29       Impact factor: 6.832

9.  Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy.

Authors:  Thasia G Woodworth; Daniel E Furst
Journal:  Arthritis Res Ther       Date:  2014-07-30       Impact factor: 5.156

10.  Infusion of autologous bone marrow mononuclear cells leads to transient reduction in proteinuria in treatment refractory patients with Idiopathic membranous nephropathy.

Authors:  Upal Sengupta; Vinod Kumar; Ashok K Yadav; Neelam Marwaha; Harbir S Kohli; Vinay Sakhuja; Vivekanand Jha
Journal:  BMC Nephrol       Date:  2013-12-01       Impact factor: 2.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.